Panobinostat is a potent histone deacetylase inhibitor (HDACi) that plays a significant role in the regulation of gene expression by altering the acetylation status of histones and other proteins. It is primarily used in the treatment of multiple myeloma, a type of blood cancer, and is marketed under the trade name Farydak.
